Company intelligence / Profile preview

Abacus Research

Seattle, Washington, United Statesabacuspi.com ↗

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Abacus Bioscience develops first-in-class active immunotherapies designed to overcome immune tolerance in chronic infections and cancers. Their platform can integrate with various cancer and viral antigens. Notable achievements include experimental drugs with structures predicted by advanced technologies like AlphaFold and multiple granted patents covering therapeutic vaccines.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Active immunotherapyMonoclonal antibodyVaccine
Industry: Biotech

Partnerships

University of WashingtonWashington Research Foundation/WRF Capital

Beyond the preview

Go deeper on Abacus Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abacus Research.

Explore the full profile